Alkermes plc ALKS R2K

Healthcare · Drug Manufacturers - Specialty & Generic · Ireland

https://www.alkermes.com

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Market & Price

Market Cap

$7.03B

Current Price

$42.19

High / Low (52W)

$42.19 / $26.13

Beta

0.26

Valuation

Stock P/E

46.88

Industry PE

23.65

Forward P/E

17.92

PEG Ratio

1.96

Book Value

$10.52

Price to Book

4.01

P/S

4.50

EV/EBITDA

29.08

Dividend Yield

Profitability & Returns

ROCE

15.63%

ROE

9.36%

ROA

4.72%

Profit Margin

9.77%

Op Margin

-0.19%

EPS (Latest Qtr)

$-0.40

EPS (TTM)

$0.90

Balance Sheet & Liquidity

Debt/Equity

0.90

Quick Ratio

1.53

Current Ratio

2.27

Debt

$1.58B

Total Assets

$2.49B

Current Assets

$1.93B

Working Capital

$1.39B

Ownership

Promoter Holding

1.44%

Chg in Prom Hold

0.02%

FII / Inst Holding

110.24%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$8.10B

Total Revenue (TTM)

$1.56B

EBITDA

$278.58M

Free Cash Flow

$140.55M

Operating Cash Flow

$256.20M

Shares Outstanding

166.68M

Gross Margin

87.45%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

9.90%

Profit 5Y

84.23%

Revenue (YoY)

28.20%

Earnings (YoY)

PROS

Profit CAGR of 84.2% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

RSI at 78 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ALKS Alkermes plc R2K	42.19	46.88	$7.03B	-	15.63%	9.36%	9.90%	84.23%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	191.78M	218.84M	217.38M	225.15M	304.64M	248.72M	223.10M	279.87M	255.24M	246.22M	247.53M	265.01M	251.43M	303.72M	294.14M	278.55M	276.22M	252.36M	287.60M	617.40M	380.94M	350.37M	399.13M	378.14M	-	306.51M	390.66M	394.19M	384.55M	392.91M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49.20M	49.46M	51.59M	46.21M	61.58M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	257.31M	341.20M	342.59M	338.34M	331.33M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	243.52M	248.22M	253.51M	280.23M	379.61M
Operating Income	-3.88M	-15.89M	-22.82M	-32.74M	-27.31M	-52.52M	-77.42M	-76.88M	-47.12M	-61.13M	-70.87M	-44.51M	-38.36M	-61.89M	-102.00K	-37.16M	-76.00M	-35.92M	-53.62M	-37.37M	-33.66M	-10.67M	-16.43M	4.42M	-19.66M	-26.59M	-34.46M	-60.64M	-10.97M	281.27M	89.19M	43.31M	109.88M	104.76M	-	13.79M	92.98M	89.08M	58.10M	-48.28M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32.91M	112.66M	108.83M	76.50M	-21.61M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	12.28M	20.89M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.49M	104.84M	100.75M	60.38M	-61.93M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.02M	17.74M	17.98M	11.04M	4.55M
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-62.51M	-32.65M	-34.44M	-96.40M	-41.99M	-52.88M	-38.65M	-29.43M	-134.00K	-22.42M	2.36M	-28.99M	-35.90M	-30.14M	-63.97M	-41.84M	237.06M	47.76M	36.83M	91.36M	92.38M	-	22.46M	87.10M	82.76M	49.34M	-66.48M
Diluted EPS	-0.06	-0.17	0.02	-0.27	-	-0.31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01	-0.18	-0.22	-0.18	-0.39	-0.25	1.38	0.28	0.21	0.53	0.55	-	0.13	0.52	0.49	0.29	-0.40
R&D Expense	45.95M	52.14M	67.21M	78.26M	70.28M	87.88M	92.56M	101.07M	97.01M	99.44M	104.83M	99.15M	104.41M	108.35M	106.82M	101.27M	102.57M	104.44M	107.67M	93.28M	94.22M	94.98M	92.27M	97.47M	118.41M	95.95M	92.87M	100.43M	63.77M	68.22M	64.88M	67.61M	59.65M	59.89M	-	71.82M	77.37M	81.74M	-	103.34M

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	745.69M	903.37M	1.09B	1.17B	1.04B	-	1.11B	1.66B	1.56B	1.48B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	218.07M	253.04M	245.33M	196.46M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	893.73M	1.41B	1.31B	1.28B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	899.82M	996.25M	891.66M	1.03B
Operating Income	-43.03M	-45.63M	-88.28M	81.81M	34.48M	-87.14M	-224.30M	-208.66M	-147.90M	-99.13M	-175.48M	-112.43M	-	-6.09M	414.12M	420.64M	253.96M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	59.77M	519.48M	494.86M	330.89M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	13.04M	23.03M	22.58M	12.28M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-31.13M	421.52M	443.75M	291.45M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	2.02M	-97.64M	71.61M	49.79M
Net Income	-39.63M	-45.54M	-113.68M	24.98M	-	-30.06M	-227.16M	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-	-158.27M	355.76M	367.07M	241.66M
Diluted EPS	-0.42	-0.48	-0.99	0.18	0.14	-0.21	-1.52	-	-	-	-	-0.70	-	-0.97	2.10	2.17	1.43
R&D Expense	95.36M	97.24M	141.89M	140.01M	-	272.04M	344.40M	387.15M	412.89M	425.41M	512.83M	394.59M	290.92M	272.70M	270.81M	245.33M	323.96M

Compounded Sales Growth

5 Years:	9.90%
1 Year:	28.20%

Compounded Profit Growth

5 Years:	84.23%
1 Year:	-

Stock Price Performance

1 Year:	+37.83%
6 Months:	+45.53%
3 Months:	+40.17%
1 Month:	+25.16%

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	452.45M	1.44B	1.47B	1.58B	1.92B	1.86B	1.73B	1.80B	1.83B	1.81B	1.95B	-	1.96B	2.14B	2.06B	2.49B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.13B	1.49B	1.42B	1.93B
Cash & Equivalents	86.89M	79.32M	38.39M	83.60M	96.96M	167.56M	224.06M	181.11M	186.38M	191.30M	266.76M	203.77M	272.96M	-	292.47M	457.47M	291.15M	388.57M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	181.42M	186.41M	182.89M	196.62M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	216.17M	229.58M	315.33M	268.62M
Total Liabilities	-	-	60.43M	581.37M	517.92M	512.40M	522.22M	541.47M	516.94M	594.42M	653.72M	719.96M	882.75M	-	920.23M	933.54M	590.59M	667.70M
Current Liabilities	-	-	48.06M	89.16M	85.93M	100.90M	130.58M	236.21M	211.99M	291.12M	339.77M	391.11M	438.26M	-	497.74M	520.22M	465.20M	543.44M
Long Term Debt	-	-	-	441.36M	362.26M	357.54M	349.01M	284.21M	280.67M	278.44M	276.46M	274.30M	272.12M	292.80M	290.27M	287.73M	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	379.44M	372.19M	75.54M	70.00M
Total Equity	434.89M	412.62M	392.02M	853.85M	952.37M	1.07B	1.40B	1.31B	1.21B	1.20B	1.17B	1.09B	1.07B	-	1.04B	1.20B	1.46B	1.82B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	168.95M	172.57M	176.67M	181.01M

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-12.25M	-5.91M	-2.48M	-	-	-40.36M	-63.80M	19.19M	99.28M	72.08M	82.84M	-	21.04M	401.35M	439.12M	520.75M
Investing Cash Flow	28.01M	5.63M	-417.16M	-	-	-43.49M	127.24M	-18.36M	-22.20M	-141.83M	-11.48M	-	-64.54M	53.36M	-111.31M	295.50M
Financing Cash Flow	-23.33M	-40.65M	464.85M	-	-	40.89M	-58.17M	4.08M	-1.62M	6.76M	-2.17M	-	-1.57M	-289.71M	-494.14M	12.38M
Capital Expenditure	-15.79M	-9.40M	-16.99M	-22.22M	-33.65M	-52.88M	-43.66M	-51.30M	-69.43M	-90.94M	-42.22M	-	-38.26M	-48.05M	-33.48M	-40.42M
Free Cash Flow	-28.03M	-15.31M	-19.47M	-	-	-93.24M	-107.46M	-32.11M	29.85M	-18.86M	40.62M	-	-17.21M	353.31M	405.64M	480.33M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-45.07M	165.00M	-166.32M	828.63M
Share Buybacks	2.68M	-	-	-	-	-	-	-	-	-	-	-	-	-	200.28M	-

Ratios (Annual)

Figures in %.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	80.4%	84.8%	84.2%	86.7%
Operating Margin %	-	-	-	-	-	-	-	-28.0%	-16.4%	-9.1%	-15.0%	-10.8%	-	-0.5%	24.9%	27.0%	17.2%
Net Margin %	-	-	-	-	-	-	-	-28.0%	-17.5%	-12.7%	-16.8%	-10.7%	-	-14.2%	21.4%	23.6%	16.4%
ROE %	-9.6%	-11.6%	-13.3%	2.6%	-	-2.2%	-17.3%	-17.2%	-13.1%	-11.9%	-18.1%	-10.4%	-	-15.2%	29.6%	25.1%	13.3%
ROCE %	-	-11.3%	-6.6%	5.9%	2.3%	-4.9%	-13.8%	-13.8%	-9.8%	-6.7%	-12.4%	-7.4%	-	-0.4%	25.6%	26.4%	13.1%

Shareholding Pattern

Insiders

1.44%

Institutions

110.24%

Public Float

111.85%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	16.99%	28.31M	$1.19B
2	Baker Bros. Advisors, LP	6.01%	10.01M	$422.42M
3	Vanguard Portfolio Management LLC	5.71%	9.51M	$401.27M
4	State Street Corporation	5.68%	9.47M	$399.34M
5	Vanguard Capital Management LLC	4.46%	7.43M	$313.36M
6	Renaissance Technologies, LLC	3.70%	6.16M	$259.91M
7	American Century Companies Inc	3.64%	6.07M	$256.18M
8	Price (T.Rowe) Associates Inc	2.80%	4.66M	$196.80M
9	Dimensional Fund Advisors LP	2.71%	4.52M	$190.80M
10	Commodore Capital Lp	2.52%	4.20M	$177.20M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALKS

No recent headlines available.

ALKS · Healthcare

Alkermes plc

About

Key Facts

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Headquarters	Ireland
Employees	2,050
Website	https://www.alkermes.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Alkermes plc ALKS R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More